VaramirStart free · no cardSign in
VTRS as of Oct 31 · 09:40 ET
VTRSNasdaqPharmaceutical Preparations

Viatris Inc · Brief

Next report

5 days

Nov 5 · before openconfirmedQ3 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
4 of 8≥ implied
avg implied
±7.7%
avg realized
±8.7%
Nov 7 '24±5.9%▲+13.52%×2.31
Feb 27 '25±7.4%▼−15.21%×2.05
May 8 '25±8.0%▲+5.70%×0.71
Aug 7 '25±8.0%▲+7.32%×0.92
Q3 FY25±7.7%▼−5.95%×0.77
Q1 FY26±8.8%▼−5.16%×0.59
May 7 '26±7.9%▲+9.03%×1.14
Q2 FY26±7.5%▼−7.71%×1.03
quarterimplied−20%0+20%realized×
Q2 FY26±7.5%▼−7.71%×1.03
May '26±7.9%▲+9.03%×1.14
Q1 FY26±8.8%▼−5.16%×0.59
Q3 FY25±7.7%▼−5.95%×0.77
Aug '25±8.0%▲+7.32%×0.92
May '25±8.0%▲+5.70%×0.71
2 older reports
Feb '25±7.4%▼−15.21%×2.05
Nov '24±5.9%▲+13.52%×2.31
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 5 report · confirmed

Bull2 of 3

1,033managers reporting a position in the latest quarterly filings13F · Jun 30 '26
+14.53%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26

Bear2 of 3

11.00%of revenue from the largest disclosed customer Cencora Inc formerly AmerisourceBergen CorporationSEC filings
10 of 25of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

VTRS report session

Suppliers 1

TBPHTheravance Biopharma×0.35
× = co-movement · max 487dSource: SEC filings · market data

Latest changes

30 daysAll changes
Oct 22impliedImplied move: ±7.3% into Nov 5 earnings (Oct 22 close).Source
Oct 88-KMaterial agreement: Agreement and Plan of Merger with Pacira BioSciences, Inc.Source
Oct 5report dateEarnings date confirmed: Nov 5.Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.